Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012
Tue, June 26, 2012
Mon, June 25, 2012

Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. at-the-jmp-securities-healthcare-conference.html
Published in Health and Fitness on Thursday, July 5th 2012 at 13:56 GMT by Market Wire   Print publication without navigation


Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference -- POINT RICHMOND, Calif., July 5, 2012 /PRNewswire/ --

Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference

[ ]
[ ]

POINT RICHMOND, Calif., July 5, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the JMP Securities Healthcare Conference in New York on July 12, 2012 at 4:00 p.m. ET.

A live audio webcast and replay of this presentation may be accessed at [ http://wsw.com/webcast/jmp18/tspt/ ] and on the Transcept Investor webpage at [ www.transcept.com ].

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit [ www.transcept.com ]. For information about Intermezzo, please visit [ www.IntermezzoRx.com ].

Contact: Transcept Pharmaceuticals, Inc. Greg Mann Sr. Director, Corporate Communications (510) 215-3567 [ gmann@transcept.com ]

 

 

 

SOURCE Transcept Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.transcept.com ]


Publication Contributing Sources